Abstract
A sensitive, precise and simple LC method for the simultaneous quantification of aliskiren, valsartan and sitagliptin in rat plasma has been developed and validated. The chromatographic separation was achieved on a C18 column (250 mm × 4.6 mm, 5 μm) maintained at room temperature, using isocratic elution with acetonitrile/20 mM ammonium acetate buffer (35:65, v/v), pH adjusted to 4.85 with glacial acetic acid, and detected using a fluorescence detector. Liquid–liquid extraction of the aliskiren, valsartan and sitagliptin from the rat plasma with t-butyl methyl ether resulted in their high recoveries. LC calibration curves based on the extracts from the rat plasma were linear in the range of 25–2,000 ng mL−1 for aliskiren and sitagliptin and 50–4,000 ng mL−1 for valsartan. The limits of quantification were 25 ng mL−1 for aliskiren and sitagliptin and 50 ng mL−1 for valsartan. The precision and accuracy of the method were well within the generally accepted criteria for biomedical analysis. The described method was successfully applied to study the pharmacokinetics of aliskiren, valsartan and sitagliptin following oral administration, individually as well as in combination in Sprague–Dawley rats. The results of the study implied the occurrence of pharmacokinetic interaction upon the co-administration of these three drugs.
Similar content being viewed by others
References
Roberts CK, Sindhu KK (2009) Life Sci 84:705–712
Barnett AH (1994) Br Med Bull 50:397–407
Grossman E, Messerli FH (2008) Adv Cardiol 45:82–106
Yarrows SA (2010) Expert Rev Cardiovasc Ther 8:19–33
Herman GA, Stein PP, Thornberry NA, Wagner JA (2007) Clin Pharmacol Ther 81:761–767
Vaidyanathan S, Jarugula V, Dieterich HA, Howard D, Dole WP (2008) Clin Pharmacokinet 47:515–531
Mistry GC, Bergman AJ, Zheng W, Hreniuk D, Zinny MA, Gottesdiener KM, Wagner JA, Herman GA, Ruddy M (2008) Br J Clin Pharmacol 66:36–42
Krishna R, Bergman A, Larson P, Cote J, Lasseter K, Dilzer S, Wang A, Zeng W, Chen L, Wagner J, Herman GA (2007) J Clin Pharmacol 47:165–174
Yamashiro W, Maeda K, Hirouchi M, Adachi Y, Hu Z, Sugiyama Y (2006) Drug Metab Dispos 34:1247–1254
Tapaninen T, Neuvonen PJ, Niemi M (2010) Clin Pharmacol Ther 88:339–342
Chu XY, Bleasby K, Yabut J, Cai X, Chan GH, Hafey MJ, Xu S, Bergman AJ, Braun MP, Dean DC, Evers R (2007) J Pharmacol Exp Ther 321:673–683
Acknowledgments
The authors wish to acknowledge the National Institute of Pharmaceutical Education and Research (NIPER)—Ahmedabad for providing all the facilities to carry out this work and Morepen Laboratories (New Delhi, India), Ranbaxy Laboratories Limited (Gurgaon, India), Cadila Pharmaceuticals Limited (Ahmedabad, India) and Sun Pharmaceutical Limited (Baroda, India) for providing aliskiren hemifumarate, valsartan, sitagliptin phosphate and irbesartan as gift samples.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Goyani, V., Rathod, R., Dash, R.P. et al. Simultaneous Quantification of Aliskiren, Valsartan and Sitagliptin by LC with Fluorescence Detection: Evidence of Pharmacokinetic Interaction in Rats. Chromatographia 76, 515–521 (2013). https://doi.org/10.1007/s10337-013-2419-5
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10337-013-2419-5